Phaseline

Companies › Nanjing RegeneCore Biotech

Nanjing RegeneCore Biotech: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 1; Respiratory, Oncology; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
RC1416–Phase 2Moderate to Severe Asthma; Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)Oct 2027
RJK-RT2831–Phase 1Hematologic MalignanciesApr 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07403487RC1416Phase 2Moderate to Severe AsthmaRespiratoryOct 2027
NCT06756451RJK-RT2831Phase 1Hematologic MalignanciesOncologyApr 2028
NCT07402551RC1416Phase 2Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)RespiratoryMay 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

SPARK Biopharma NuvOx ImmuneOncia Therapeutics MiNK Therapeutics Guangzhou JOYO Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.